Tuesday June 2, 2020

Price still isn’t right for Biogen’s blockbuster drug

HSE says Spinraza drug for SMA sufferers would cost €38 million over five years, as pharma giant clocks up global annual sales of $1.72 billion

Susan Mitchell

Deputy Editor and Health Editor

3rd March, 2019
Michel Vounatsos, CEO, Biogen n Vounatsos was paid $13.6 million in pay, shares and other compensation in 2017

Biogen’s Spinraza clocked up global sales of $1.72 billion for the company last year.

It is being reimbursed by numerous health systems across Europe - but to varying degrees.

The HSE told Biogen that it would not reimburse Spinraza at the price it was offering.

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Elderly now required to isolate for 14 days inside care homes once discharged from hospital

Susan Mitchell | 2 days ago

Home care firms group calls for statutory home care scheme to allow people to remain at home if they wish

Susan Mitchell | 2 days ago

Many patients may have physical, cognitive and psychological disabilities and will need long-term management

Danielle Barron | 2 days ago